Business Context and Reporting Period
Company: Assembly Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 22, 2026
Principal Executive Offices: South San Francisco, California
This filing discloses a strategic expansion of the clinical development program for ABI-6250 ("6250"), an oral entry inhibitor candidate. Originally developed for chronic hepatitis delta virus (HDV) infection, the program is being broadened to include primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), targeting cholestatic liver diseases.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical development updates and regulatory disclosures.
Material Changes and Clinical Progress
- Program Expansion: 6250 is expanding from HDV into PBC and PSC based on preclinical data, pharmacologic profile, and Phase 1a findings.
- Mechanism of Action: 6250 is an investigational oral small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP). It blocks bile acid uptake into liver cells, addressing the mechanism driving inflammation in cholestatic diseases.
- Phase 1a Status: Completed in healthy participants. Data demonstrated target engagement via dose-dependent elevations in plasma total bile acids.
- Toxicology: Chronic toxicology studies are complete and support potential for longer-term dosing in Phase 2 trials.
Guidance, Outlook, and Risks
Development Timeline
- HDV Program: Phase 2 clinical study expected to initiate in the fourth quarter of 2026.
- Cholestatic Liver Diseases (PBC/PSC): A Phase 2 basket study is expected to begin in the first quarter of 2027, subject to regulatory feedback.
Regulatory Engagement
The Company recently held a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the cholestatic liver disease development plan. While official minutes are pending, management characterized the discussion as constructive and helpful.
Risks and Contingencies
- Investigational Status: 6250 has not been approved globally; safety and efficacy remain unestablished.
- Market Need: While multiple therapies exist for PBC, many patients have inadequate responses. There are currently no approved therapies for PSC.
- Regulatory Dependency: The 2027 start date for the PBC/PSC study is contingent upon regulatory feedback.
Investor Verification Checklist
- Verify the official FDA pre-IND meeting minutes once released to confirm specific regulatory guidance.
- Monitor the initiation of the Phase 2 HDV study in Q4 2026 and the Phase 2 basket study in Q1 2027.
- Review the attached press release (Exhibit 99.1) for detailed preclinical data supporting the expansion into PBC and PSC.
- Assess the Company's cash runway and capital requirements to fund the expanded clinical programs, as no financial data is provided in this filing.